中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 35 Issue 4
Apr.  2019
Turn off MathJax
Article Contents

Influence of intestinal dysbacteriosis on liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2019.04.040
Research funding:

 

  • Published Date: 2019-04-20
  • Liver cirrhosis is a progressive chronic liver disease due to one or more causes, with diffuse fibrosis in liver tissue, pseudolobules, and regenerative nodules as major histological features. Once liver cirrhosis enters the decompensated stage, the liver and several other organs are injured, which can hardly be recovered or reversed. This article introduces the process of Toll-like receptors in recognizing the changes in intestinal flora and the influence of this process on the development and progression of liver cirrhosis, as well as the protective effect of bile acid against liver cirrhosis by regulating intestinal flora. This article also reviews the advances in delaying liver cirrhosis after the treatment of intestinal dysbacteriosis and points out that the treatment of intestinal dysbacteriosis may become the major direction of liver cirrhosis treatment in future.

     

  • loading
  • [1]BRENNER DA, PAIK YH, SCHNABL B. Role of gut microbiota in liver disease[J]. J Clin Gastroenterol, 2015, 49 (Suppl 1) :s25-s27.
    [2]ZHANG Y, FENG Y, CAO B, et al. The effect of small intestinal bacterial overgrowth on minimal hepatic encephalopathy in patients with cirrhosis[J]. Arch Med Sci, 2016, 12 (3) :592-596.
    [3]PURI P, SANYAL AJ. The intestinal microbiome in nonalcoholic fatty liver disease[J]. Clin Liver Dis, 2018, 22 (1) :121-132.
    [4]BORRELLI A, BONELLI P, TUCCILLO FM, et al. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma:Current and innovative therapeutic approaches[J]. Redox Biol, 2018, 15:467-479.
    [5]SHAH A, SHANAHAN E, MACDONALD GA, et al. Systematic review and meta-analysis:Prevalence of small intestinal bacterial overgrowth in chronic liver disease[J]. Semin Liver Dis, 2017, 37 (4) :388-400.
    [6]KONG L, LU Y, ZHANG S, et al. Role of nutrition, gene polymorphism, and gut microbiota in non-alcoholic fatty liver disease[J]. Discov Med, 2017, 24 (131) :95-106.
    [7]LI W, ZHANGK, YANG H. Pectin alleviates high fat (lard) Diet-induced nonalcoholic fatty liver disease in mice:Possible role of short-chain fatty acids and gut microbiota regulated by pectin[J]. J Agric Food Chem, 2018, 66 (30) :8015-8025.
    [8]ALTAMIRANO-BARRERA A, URIBE M, CHAVEZ-TAPIA NC, et al. The role of the gut microbiota in the pathology and prevention of liver disease[J]. J Nutr Biochem, 2018, 60:1-8.
    [9]ZHU L, BAKER RD, BAKER SS. Gut microbiome and nonalcoholic fatty liver diseases[J]. Pediatr Res, 2015, 77 (1-2) :245-251.
    [10]CAHOVA M, BRATOVA M, WOHL P. Parenteral nutrition-associated liver disease:The tole of the gut microbiota[J]. Nutrients, 2017, 9 (9) :987.
    [11]WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60 (1) :197-209.
    [12]DAVIS BC, BAJAJ JS. The human gut microbiome in liver diseases[J]. Semin Liver Dis, 2017, 37 (2) :128-140.
    [13]TILG H, CANI PD, MAYER EA. Gut microbiome and liver diseases[J]. Gut, 2016, 65 (12) :2035-2044.
    [14]WEN Z, JI X, TANG J, et al. Positive feedback regulation between transglutaminase 2 and Toll-Like receptor 4 signaling in hepatic stellate cells correlates with liver fibrosis post schistosoma japonicum Infection[J]. Front Immunol, 2017, 8:1808.
    [15]YAN C, LI B, FAN F, et al. The roles of Toll-like receptor 4 in the pathogenesis of pathogen-associated biliary fibrosis caused by Clonorchis sinensis[J]. Sci Rep, 2017, 7 (1) :3909.
    [16]KANG HH, KIM IK, LEE HI, et al. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity via TLR4/MyD88/MAPK/NF-kB signaling pathways[J]. Biochem Biophys Res Commun, 2017, 490 (2) :349-355.
    [17]KUMAR S, WANG J, SHANMUKHAPPA SK, et al. Toll-Like receptor 4-independent carbon tetrachloride-induced fibrosis and lipopolysaccharide-induced acute liver injury in mice:role of hepatic stellate cells[J]. Am J Pathol, 2017, 187 (6) :1356-1367.
    [18]GOMEZ-HURTADO I, SUCH J, FRANCES R. Microbiome and bacterial translocation in cirrhosis[J]. Gastroenterol Hepatol, 2016, 39 (10) :687-696.
    [19]BAJAJ JS, BETRAPALLY NS, GILLEVET PM. Decompensated cirrhosis and microbiome interpretation[J]. Nature, 2015, 525 (7569) :e1-e2.
    [20]SINGH A, CRESCI GA, KIRBY DF. Proton pump inhibitors:Risks and rewards and emerging consequences to the gut microbiome[J]. Nutr Clin Pract, 2018, 33 (5) :614-624.
    [21]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J/CD]. Chin J Liver Dis:Electronic Edition, 2018, 10 (4) :17-32. (in Chinese) 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南[J/CD].中国肝脏病杂志:电子版, 2018, 10 (4) :17-32.
    [22]YILDIZ S, DOGAN I·, DOGRUMAN-Al F, et al. Association of enteric protist blastocystis spp and gut microbiota with hepatic encephalopathy[J]. J Gastrointestin Liver Dis, 2016, 25 (4) :489-497.
    [23]LACHAR J, BAJAJ JS. Changes in the microbiome in cirrhosis and relationship to complications:Hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis[J]. Semin Liver Dis, 2016, 36 (4) :327-330.
    [24]ACHARYA C, BAJAJ JS. Gut microbiota and complications of liver disease[J]. Gastroenterol Clin North Am, 2017, 46 (1) :155-169.
    [25]SANTIAGO A, POZUELO M, POCA M, et al. Alteration of the serum microbiome composition in cirrhotic patients with ascites[J]. Sci Rep, 2016, 6:25001.
    [26]AITBAEV KA, MURKAMILOV IT, FOMIN VV. Liver diseases:The pathogenetic role of the gut microbiome and the potential of treatment for its modulation[J]. Ter Arkh, 2017, 89 (8) :120-128.
    [27]ZAPATER P, GONZALEZ-NAVAGAS JM, SUCH J, et al. Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis[J]. World J Gastroenterol, 2015, 21 (41) :11493-11501.
    [28]PONZIANI FR, GERARDI V, PECERE S, et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications[J]. World J Gastroenterol, 2015, 21 (43) :12322-12333.
    [29]GOMEZ-HURTADO I, GIMENEZ P, GARCIA I, et al. Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis[J]. Liver Int, 2018, 38 (2) :295-302.
    [30]SARANGI AN, GOEL A, SINGH A, et al. Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration[J]. BMC Gastroenterol, 2017, 17 (1) :125.
    [31]SUN YP, GUO XX. Clinical effect of probiotics in treatment of liver cirrhosis:A meta-analysis[J]. J Clin Hepatol, 2018, 34 (1) :73-79. (in Chinese) 孙元培, 郭晓霞.微生态制剂治疗肝硬化的Meta分析[J].临床肝胆病杂志, 2018, 34 (1) :73-79.
    [32]LIU J, FU UY, ZHANG H, et al. The hepatoprotective effect of the probiotic Clostridium butyricum against carbon tetrachloride-induced acute liver damage in mice[J]. Food Funct, 2017, 8 (11) :4042-4052.
    [33]LAVEKAR AS, RAJE DV, MANOHAR T, et al. Role of probiotics in the treatment of nonalcoholic fatty liver disease:A meta-analysis[J]. Euroasian J Hepatogastroenterol, 2017, 7 (2) :130-137.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1404) PDF downloads(286) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return